Maurie Markman, MD Hello. I am Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia, Pennsylvania. I wanted to briefly highlight the recently updated US Food and Drug Administration (FDA) assessment on the use of laparoscopic power morcellators to treat uterine fibroids. This is clearly a complex and controversial topic, and one that…
Nevertheless, She Persisted: Women Face Unique Obstacles When Pursuing Surgery as a Specialty
Anya Romanowski, MS, RD The Role of Gender and Perception in Surgical Specialty Choice In the United States and abroad, there is a growing public reckoning over the routine discrimination and harassment that many women have faced in the workplace. The field of surgery has not been immune to these larger upheavals. Although surgery remains…
Vitamin and Mineral Supplements: Which Patients Will Benefit?
JoAnn E. Manson, MD, DrPH Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston, Massachusetts. I’d like to talk with you today about vitamin and mineral supplements. Is there a rational approach? Most of our patients are taking dietary supplements, usually vitamin or mineral supplements, and we…
‘This Mole Looks Strange’ – Dermatology for the Primary Care Clinician
Author: Charles P. Vega, MD; Temitayo A. Ogunleye, MD Clinicians see many skin conditions in the primary care setting. Medscape talked with a primary care clinician, Charles P. Vega, MD, and a dermatologist, Temitayo A. Ogunleye, MD, to learn their thoughts on how to best diagnose and manage dermatology-related symptoms in primary care. This consultation is…
Costly Rare Cancer Drugs Fund Fails to Provide Clinical Benefit
Author: David J. Kerr, CBE, MD, DSc, FRCP, FMedSci Hello. I am David Kerr, professor of cancer medicine from the University of Oxford, England. I want to talk about an interesting paper I picked up recently in Annals of Oncology.[1] This was prepared and presented by Dr Aggarwal from Richard Sullivan’s group at Kings College London. They have done a lot…
Sofosbuvir: A novel treatment option for chronic hepatitis C infection
Author: Harmeet Kaur Bhatia, Harmanjit Singh,1 Nipunjot Grewal,2 and Navreet Kaur Natt3 Abstract Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality. The current standard of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks, along with pegylated…
